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ABSTRACT
Background: An increasing number of randomized placebo-controlled trials 
involving traditional Chinese medicine (TCM) compound formulations have been 
implemented worldwide.
Objective: The aim of this study was to assess the reporting quality, scientific 
rigor, and ethics of randomized placebo-controlled trials of TCM compound formula-
tions and compare these differences between Chinese and non-Chinese trials.
Methods: English-language databases included the following: PubMed, OVID, 
EMBASE, and Science Citation Index Expanded. Chinese-language databases in-
cluded the following: Chinese Biomedical Literature Database, Wanfang Database, 
Chinese Scientific and Technological Periodical Database, and the China National 
Knowledge Infrastructure. All were searched from respective inception to March 2009 
to identify randomized placebo-controlled trials involving TCM compound prescrip-
tions. Two reviewers independently assessed the retrieved trials via a modified Con-
solidated Standard of Reporting Trials (CONSORT) checklist and some evaluation 
indices that embodied the TCM characteristics or the scientific rigor and ethics of 
placebo-controlled trials. Trial publishing time was divided into 3 intervals: phase 1 
(≤1999); phase 2 (2000–2004); and phase 3 (2005–2009). The number and percent-
age of trials reporting each item and the corresponding differences between Chinese 
(mainland China, Hong Kong, and Taiwan) and non-Chinese (eg, Japan, United States, 
Australia, Korea, and United Kingdom) trials were calculated. Moreover, the influ-
ence of trial publishing time on the reporting of CONSORT items and the differences 
in the number of items reported for each time interval between Chinese and non-Chinese 
trials were assessed.
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Results: A total of 324 trials from China and 51 trials from other countries 
were included. A mean of 39.7% of the CONSORT items across all Chinese trials and 
50.2% of the items across all non-Chinese trials were reported. The number of the 
reported CONSORT items all increased over time in both groups and the gap be-
tween Chinese articles and non-Chinese articles gradually decreased. Additionally, of 
the 324 Chinese articles, 137 (42.28%) reported TCM syndrome type, 113 (34.88%) 
reported the diagnostic criteria of diseases for TCM, and 69 (21.30%) reported effi-
cacy evaluation indices of TCM. Of the non-Chinese articles, 3 (5.88%) reported TCM 
syndrome type and 1 (1.96%) reported the diagnostic criteria of diseases and evalua-
tion indices of efficacy for TCM. It was found that 45.37% and 6.17% of Chinese 
articles reported the standard intervention for the diseases being treated and the emer-
gency plan, respectively, compared with 23.53% and 9.80% for the non-Chinese ar-
ticles; 33.02% and 10.49% of Chinese articles reported informed consent and ethics 
committee approval, respectively, compared with 92.16% and 82.35% for the non-
Chinese articles. With regard to placebo ethics, 38.89% of the Chinese trials and 
23.53% of the non-Chinese trials found it would not be ethically acceptable to use 
placebo alone in the control group.
Conclusions: The data indicate that the reporting quality of the included 
trials on TCM compounds has improved over time, but still remains poor regardless 
of Chinese or non-Chinese trials. Across all trials, particularly Chinese trials, the re-
porting of the CONSORT items was inadequate (39.7%). The difference in the mean 
number of the reported CONSORT items between Chinese trials and non-Chinese 
trials narrowed from phase 1 (10.0 vs 13.8) to phase 3 (14.4 vs 17.4). Moreover, a large 
number of trials, especially non-Chinese trials (94.1%), were lacking syndrome dif-
ferentiation of TCM. More importantly, in many placebo-controlled trials, especially 
Chinese trials, the use of placebo was not justified and was ethically contradictory. 
(Curr Ther Res Clin Exp. 2010;71:30–49) © 2010 Excerpta Medica Inc.
Key words: reporting quality, scientific rigor, ethics, traditional Chinese 
medicine compound formulation, placebo, randomized controlled trial, CONSORT 
statement.
INTRODUCTION
With the advancement of science, medical technology has witnessed rapid improve-
ment.1 However, for certain diseases, there is still a lack of effective treatment meth-
ods. Therefore, both doctors and patients may turn to complementary and alternative 
medicine (CAM)2 such as traditional Chinese medicine (TCM).3–6 TCM is a medical 
system in China that has been used for thousands of years to diagnose and treat dis-
eases.3 The recognition and treatment of diseases in TCM are different from those in 
Western medicine. TCM theories are based on syndrome differentiation and holistic 
medicine. It includes treatments such as Chinese herbal medicine, acupuncture, and 
Qigong.7 A formulation that contains ≥2 Chinese herbs8 better conforms to TCM 
theories and better reflects the characteristics of TCM than the administration of a 
single herb. Generally, a compound formulation is prescribed according to the principle 
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“Monarch, Minister, Assistant and Guide.” The Monarch acts as the chief drug for 
treating the disease and is composed of one or more herbs; the Minister serves to in-
tensify the effect of the Monarch drug; the Assistant helps to deals with the secondary 
symptoms or inhibits the toxicity of the Monarch drug; and the Guide drug leads the 
other herbs to the diseased parts and balances the effects of all herbs. TCM compound 
formulations have been widely used to treat disease in China. In recent decades, the 
use of TCM has become more popular, sometimes as a complementary treatment to 
Western medicine, throughout the world.9,10 TCM has been adopted in modified 
forms in other countries, such as Korea, Japan, United States, and Australia.11
In the past 2 decades, randomized, double-blind, placebo-controlled, clinical trials 
have been considered the general standard in clinical research of therapeutic interven-
tions.12 An increasing number of randomized placebo-controlled trials of TCM com-
pound formulations have been designed and implemented.13 However, the reporting 
quality of these trials or whether placebo-controlled trials meet the requirements of 
scientific rigor and ethics is unclear.
Some research has revealed that the reporting quality of TCM trials was poor. Gag-
nier et al14 found that randomized controlled trials (RCTs) of herbal medicine inter-
ventions reported less than half of the necessary information of the modified Consoli-
dated Standard of Reporting Trials (CONSORT) items. Wang et al15 assessed the 
reporting quality of RCTs of TCM interventions in 13 randomly selected journals 
from mainland China, which indicated that only 39.4% of the modified CONSORT 
items were reported across all included trials. However, a search of the literature re-
vealed that there had been no articles that assessed the reporting quality, scientific 
rigor, and ethics of randomized placebo-controlled trials of TCM compound prescrip-
tion interventions.
The CONSORT statement was first published in 1996 and revised in 2001.16,17 It 
was gradually introduced into China after 2001.18 It has been endorsed by many lead-
ing medical journals and has been widely accepted as an international standard to 
improve the reporting quality of RCTs.19 It includes a 22-item checklist and a flow 
diagram to guide researchers and writers on how to design and report clinical trials.16
Adequate reporting is defined as reporting all items recommended by the CONSORT 
guidelines. Previous research indicates that the use of the CONSORT statement 
might help to improve the quality of reports of RCTs.20 It is, however, not enough to 
assess the reporting quality of RCTs of TCM through the information suggested in 
CONSORT. In order to improve the reporting quality of RCTs of TCM, the Chinese 
Cochrane Center was authorized to establish CONSORT for TCM. In 2006, the draft 
version was completed.21 However, some items still need further improvement. 
Therefore, after consultation with some experts of Chinese Evidence-Based Medicine/
Cochrane Center, our research team jointly established a modified CONSORT 
checklist, some specific indices that reflect the characteristics of TCM, and other 
indices that should be reported in placebo-controlled trials, which were based on 
the CONSORT for TCM. This was done to be able to assess the reporting quali- 
ty of randomized placebo-controlled trials of TCM compound formulation 
interventions.
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The objective of the present study was to assess the reporting quality, scientific 
rigor, and ethics of randomized placebo-controlled trials of TCM compound formula-
tion interventions. A secondary objective was to compare the corresponding differ-
ences between Chinese and non-Chinese trials.
METHODS
Literature Search Strategy
A literature search was conducted of 8 electronic databases including 4 English-
language databases and 4 Chinese-language databases, from respective inception to 
March 2009. English language databases included the following: PubMed, OVID, 
EMBASE, and Science Citation Index Expanded. Chinese language databases included 
the following: Chinese Biomedical Literature Database, Wanfang Database, Chinese 
Scientific and Technological Periodical Database, and the China National Knowledge 
Infrastructure. The search terms used in PubMed were as follows: (“Placebos”[Mesh] 
OR placebo* OR sham) AND (“Medicine, Chinese Traditional”[Mesh] OR herb*). The 
search terms were similar for all databases. The publication type of articles was limit-
ed to RCTs, and the language of articles was limited to English and Chinese.
Study Selection
Articles that satisfied the criteria of randomized placebo-controlled clinical trials of 
TCM compound prescription interventions were identified. Exclusion criteria were as fol-
lows: experimental studies; nonclinical research (eg, methodologic studies, systematic re-
views, meta-analyses, and other review literature); and duplicate studies. In addition, some 
articles involving CAM other than TCM compound formulations, herb medicine mono-
mer, or single herb as the intervention group were excluded. Two authors (X.-M.L. and 
J.-J.F.) independently screened the title and abstract of each article to determine its eligi-
bility for inclusion. When trial inclusion could not be determined by titles and 
abstracts, full texts were retrieved. Disagreements were resolved by consensus.
Assessment Contents
The CONSORT checklist was reviewed and 33 subitems extracted from the original 
22-item CONSORT statement22 formed a modified CONSORT checklist (Table I). 
Each subitem referred to an individual concept.
In addition, we summarized some TCM characteristic indices based on the state-
ment of CONSORT for TCM as well as other indices that should be reported in 
placebo-controlled trials. Indices, which reflected the TCM characteristics, included 
the composition of each TCM compound, actions and indications of each TCM 
compound, and modern pharmacologic evidence of each active ingredient, TCM syn-
drome type, TCM diagnostic criteria for each disease, evaluation indices of efficacy for 
TCM, and interpretation of the results with TCM theories.21 Some indices that should 
be reported in placebo-controlled trials included the manufacturing process of the 
placebo, the difference in sensory characteristics between the study preparation and 
the placebo, quality control surveillance of interventions, and number and name of 
trial registration (Table II). The use of placebo, which should smell, appear, and 
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Table I.  The modified Consolidated Standard of Reporting Trials (CONSORT) checklist for reporting randomized placebo 
controlled trials of traditional Chinese medicine compound formulations.
Study 
Section
Standard 
CONSORT 
Items
Item 
No.
          Subitem Description 
         of CONSORT Checklist
Chinese 
Trials,* No. (%) 
(n = 324)
Non-Chinese 
Trials,† No. (%) 
(n = 51)
Statistic 
Value P
Title and 
abstract
Title and 
abstract
 1 How participants were allocated to 
interventions 302 (93.21) 45 (88.24) 0.940‡ 0.332
Introduction Background  2 Scientiﬁc background and 
explanation of rationale 267 (82.41) 51 (100) 10.580§ 0.001
Methods Participants  3 Inclusion criteria for participants 291 (89.81) 51 (100) 4.497‡ 0.034
 4 Exclusion criteria for participants 204 (62.96) 40 (78.43) 4.638§ 0.031
 5 The settings and locations where 
the data were collected 217 (66.98) 33 (64.71) 0.102§ 0.749
Interventions  6 Precise details of the interventions 
intended for each group 150 (46.30) 34 (66.67) 7.316§ 0.007
Objectives  7 Speciﬁc objectives and hypotheses 316 (97.53) 50 (98.04) 0.000‡ 1.000
Outcomes  8 Clearly deﬁned primary outcome 
measures 55 (16.98) 22 (43.14) 18.483§ <0.001
 9 Clearly deﬁned secondary outcome 
measures 27 (8.33) 17 (33.33) 26.592§ <0.001
10 Any methods used to enhance the 
quality of measurements 37 (11.42) 3 (5.88) 1.418§ 0.234
Sample size 11 How sample size was determined 18 (5.56) 18 (35.29) 41.543‡ <0.001
(continued)
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Study 
Section
Standard 
CONSORT 
Items
Item 
No.
          Subitem Description 
         of CONSORT Checklist
Chinese 
Trials,* No. (%) 
(n = 324)
Non-Chinese 
Trials,† No. (%) 
(n = 51)
Statistic 
Value P
Randomization 
sequence 
generation
12 Method used to generate the 
random allocation sequence 104 (32.10) 20 (39.22) 1.008§ 0.315 
13 Details of any restriction of 
randomization 39 (12.04) 13 (25.49) 6.677§ 0.010
Allocation 
concealment
14
Allocation concealment 23 (7.10) 9 (17.65) 5.003‡ 0.025
Randomization 
implementation
15 Who generated the allocation 
sequence, who enrolled 
participants, and who assigned 
participants to their groups 18 (5.56) 7 (13.73) 3.505‡ 0.061
Blinding 16 Whether or not participants were 
blinded to group assignment 205 (63.27) 49 (96.08) 21.700§ <0.001
17 If done, how the success of blinding 
was evaluated 5 (1.54) 4 (7.84) 5.019‡ 0.025
Statistical 
methods
18 Statistical methods used to 
compare groups for primary 
outcome(s) 254 (78.40) 48 (94.12) 6.948§ 0.008
19 Methods for additional analyses, 
such as subgroup and adjusted 
analyses 6 (1.85) 2 (3.92) 0.185‡ 0.668
(continued)
Table I (continued).
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Table I  (continued).
Study 
Section
Standard 
CONSORT 
Items
Item 
No.
          Subitem Description 
         of CONSORT Checklist
Chinese 
Trials,* No. (%) 
(n = 324)
Non-Chinese 
Trials,† No. (%) 
(n = 51)
Statistic 
Value P
Results Participant flow 20 Flow of participants through each 
stage 13 (4.01) 18 (35.29) 52.810‡ <0.001
21 Describe protocol deviations from 
study as planned, together with 
reasons 12 (3.70) 7 (13.73) 7.235‡ 0.007
Recruitment 22 Dates deﬁning the periods of 
recruitment 216 (66.67) 15 (29.41) 25.855§ <0.001
23 Dates deﬁning the periods of 
follow-up 54 (16.67) 23 (45.10) 21.829§ <0.001
Baseline data 24 Baseline demographic and clinical 
characteristics of each group 257 (79.32) 40 (78.43) 0.021§ 0.884
Numbers 
analyzed
25 Intention-to-treat analysis 25 (7.71) 12 (23.53) 12.390§ <0.001
Outcomes and 
estimation
26 For each primary and secondary 
outcome, a summary of results for 
each group 320 (98.77) 51 (100) _ 1.000•
27 For each primary and secondary 
outcome, the estimated effect size 83 (25.62) 6 (11.76) 4.671§ 0.031
28 The estimated effect precision (eg, 
95% CI) 13 (4.01) 8 (15.69) 9.258‡ 0.002
(continued)
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Table I  (continued).
Study 
Section
Standard 
CONSORT 
Items
Item 
No.
          Subitem Description 
         of CONSORT Checklist
Chinese 
Trials,* No. (%) 
(n = 324)
Non-Chinese 
Trials,† No. (%) 
(n = 51)
Statistic 
Value P
Ancillary 
analyses
29 Ancillary analyses 4 (1.23) 2 (3.92) _ 0.190•
Adverse events 30 Adverse events in each intervention 
group 154 (47.53) 35 (68.63) 7.845§ 0.005
Discussion Interpretation 31 Interpretation of the results, taking 
into account study hypotheses, 
sources of potential bias or 
imprecision 82 (25.31) 26 (50.98) 14.162§ <0.001
Generalizability 32 Generalizability of the trial findings 244 (75.31) 31 (60.78) 4.753§ 0.029
Overall 
evidence
33 General interpretation of the results 
in the context of current evidence
85 (26.23) 24 (47.06) 9.268§ 0.002
*Trials conducted in mainland China, Hong Kong, and Taiwan.
†  Trials conducted outside of mainland China (eg, Japan, United States, Australia, Korea, and United Kingdom).
‡ Continuity correction χ2 test.
§ Pearson χ2 test.
•   Fisher exact test.
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Table II.  Comparison of the number of Consolidated Standard of Reporting Trials (CONSORT) items reported for each time inter-
val between Chinese and non-Chinese trials in randomized placebo-controlled trials of traditional Chinese medicine 
compound formulations.
Chinese Trials* Non-Chinese Trials† 
 (n = 324) (n = 51) 
  CONSORT  CONSORT 
  Items  Items 
  Reported,  Reported,  
 No. Mean (SD),  No. Mean (SD) Statistic 
Trial Publishing Time of Trials No. of Trials No. Value P
Phase 1 (≤1999) 40 10.0 (3.0) 12 13.8 (4.3) 3.487‡ 0.001
Phase 2 (2000–2004) 73 11.1 (2.6) 23 17.4 (3.8) –5.945§ <0.001
Phase 3 (2005–2009) 211 14.4 (3.8) 16 17.4 (4.5) –2.526§ 0.012
From inception to March 2009 324 13.1 (3.9) 51 16.6 (4.3) –5.043§ <0.001
*Trials conducted in mainland China, Hong Kong, and Taiwan.
†  Trials conducted outside of mainland China (eg, Japan, United States, Australia, Korea, and United Kingdom).
‡ Independent samples t test.
§  Analyses were performed using the Wilcoxon rank sum test because homogeneity of variance assumptions was not met.
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taste indistinguishably from the trial preparation while pharmacologic action and 
toxicity were absent, aims to eliminate bias caused by psychological factors in research-
ers, subjects, and evaluators during the assessment of the effectiveness of drugs.23
The scientific rigor and ethics of placebo-controlled trials were assessed using some self-
designed indices, which included the number of trials acceptable to use placebo alone, 
basic interventions of diseases, emergency plan against aggravated disease conditions, in-
formed consent obtained from subjects, and ethics committee approval. The Guideline 11 
proposed by the Council for International Organizations of Medical Sciences in October 
200224 was used to judge the ethical acceptability of placebo application.
Data Extraction
All included trials were classified into 2 groups: Chinese (conducted in mainland 
China, Hong Kong, and Taiwan) and non-Chinese (eg, Japan, United States, Austra-
lia, Korea, and United Kingdom) trials. All reviewers were trained at the Chinese 
Evidence-Based Medicine/Cochrane Center, Chengdu, China. Two authors (B.M. and 
H.-M.Y) assessed each included trial independently. Each item was assigned a yes 
or no response depending on whether the item was included in the report. Each yes 
response earned 1 point. Disagreements were resolved by consensus. If needed, a third 
authors (G.-J.L.) was consulted. The number and percentage of trials reporting each 
item were calculated, and the difference of each assessment item between the 2 groups 
was compared. Trial publication date was divided into 3 intervals: phase 1 (≤1999); 
phase 2 (2000–2004); and phase 3 (2005–2009). We tested the influence of publica-
tion date on the number of CONSORT items reported and compared the differences 
between the 2 groups for each time interval.
Statistical Analysis
Data of normal distribution were presented as mean (SD). All of the statistical 
analyses were performed by one individual (T.F.) using SPSS for Windows, version 
11.5 (SPSS Inc., Chicago, Illinois). Cohen’s κ was calculated for interrater reliability 
on reporting quality assessments. The percentage of trials reporting each item in the 
2 groups was compared using the Pearson χ2 test (the minimum expected count ≥5), 
continuity correction χ2 test (1 ≤ the minimum expected count <5), or the Fisher 
exact test (the minimum expected count <1). The differences in the number of re-
ported CONSORT items for each time interval between the 2 groups were analyzed 
by t test, if the homogeneity of variance assumptions was met or the Wilcoxon rank 
sum test if it was not. The multiple comparisons of the differences in each group were 
performed using 1-way ANOVA, followed by a Newman-Keuls post hoc test. P < 
0.05 was considered to be statistically significant.
RESULTS
A total of 905 potentially relevant articles were identified from the initial search, of 
which 47 duplicate literature and 36 experimental studies were excluded. After ex-
amination of titles and abstracts, 58 articles were excluded due to nonclinical research. 
Another 389 articles that involved CAM other than TCM compound formulations, 
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herb medicine monomer, or single herb as the intervention group were further exclud-
ed. Finally, 375 trials were included, of which 324 were Chinese trials and 51 were 
non-Chinese trials (Figure 1).
Interrater reliability was used to test values from each reviewer and Cohen’s κ was 
0.721, indicating low interobserver variability.25 Table I outlines the number and 
percentage of trials reporting each of the 33 modified CONSORT items and the cor-
responding differences between the 2 groups. The results indicated that the reporting 
information was inadequate regardless of which group, particularly in terms of clear- 
ly defined outcome measures (subitems 8, 9), methods used to enhance the quality 
of measurements (subitem 10), estimation of sample size (subitem 11), method of 
random-sequence generation (subitem 12), allocation concealment (subitem 14), 
implementation of randomization (subitem 15), evaluation of blinding (subitem 17), 
flow diagram (subitem 20), estimated effect size and its precision (subitems 27, 28), 
and interpretation of the results (subitems 31, 33). Reporting information was signifi-
cantly less in Chinese trials compared with non-Chinese trials for the following items: 
description of scientific background (P = 0.001); inclusion and exclusion criteria for 
participants (P = 0.034 and P = 0.031, respectively); precise details of the interven-
tions (P = 0.007); clear definition of outcome measures (P < 0.001); estimation of 
sample size (P < 0.001); allocation concealment (P = 0.025); implementation and 
evaluation of blinding (P < 0.001 and P = 0.025, respectively); description of statisti-
cal methods (P = 0.008); flow diagram (P < 0.001); intention-to-treat analysis (P < 
0.001); description of adverse events (P = 0.005); and interpretation and generalizabili- 
ty of the results (P < 0.001 and P = 0.029, respectively). 
The mean (SD) number of CONSORT items reported across all Chinese trials was 
13.1 (3.9) or 39.7% of the 33 items, while that of non-Chinese trials was 16.6 (4.3) 
or 50.2%. Comparisons of the mean number of CONSORT items reported for each 
time interval between the 2 groups are presented in Table II and shown in Figure 2. 
The Q statistic was used to compare all pairs of means following 1-way ANOVA. 
Multiple comparisons with the Q statistic revealed that, in Chinese trials, there were 
no significant differences in the mean number of CONSORT items reported between 
phases 1 and 2 (P = NS), but phase 3 significantly increased compared with phases 1 
and 2 (P < 0.05). In non-Chinese trials, there was no significant difference between 
phases 2 and 3 (P = NS), but both were significantly increased compared with phase 
1 (both, P < 0.05). The mean number of CONSORT items reported in the included 
articles all increased over time regardless of group, and for each time interval, the 
mean number of items reported in Chinese articles was significantly less than that 
reported in non-Chinese articles (P < 0.05). However, the mean number of items re-
ported in Chinese articles grew continuously, whereas in non-Chinese articles it grew 
rapidly before 2004, but relatively slower after 2004. Moreover, compared with non-
Chinese articles from 2000 to 2004, contemporaneous Chinese articles lagged far 
behind in terms of the mean number of reported CONSORT items, but the difference 
decreased after 2005.
Table III shows the assessment outcomes of TCM characteristic indices and other 
indices that should be reported in placebo-controlled trials. The reported information 
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Potential relevant literature (n = 668)
Eligible literature (n = 375)
Chinese trials (n = 324)
  Mainland China (306)
  Hong Kong (10)
  Taiwan (8)
Non-Chinese trials (n = 51)
  Japan (17)
  United States (8)
  Australia (6)
  Korea (4)
  United Kingdom (3)
  India (3)
  Israel (3)
  Germany (2)
  Other (5)
Articles excluded for the following reason:
  Herb medicine monomer or single herb
  in the intervention group (n = 293)
Total number of potentially relevant literature identied (N = 905)
Potential relevant literature (n = 858)
Potential relevant literature (n = 822)
Potential relevant literature (n = 764)
Duplicate literature (n = 47)
Animal experiments (n = 36)
Nonclinical researches (n = 58)
  Methodologic studies
  Systematic reviews or meta-analyses
  Other review literature
Articles excluded for the following reason:
  Complimentary and alternative medicine
  other than traditional Chinese medicine
  compound formulation in the
  intervention group (n = 96)
Figure 1. Flow chart showing the article selection process and reasons for exclusion.
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regarding the characteristics of TCM was considered inadequate in both groups. The re-
sults indicated significant differences between the 2 groups in certain indices, such as 
syndrome type and diagnostic criteria of TCM (both, P < 0.001), evaluation indices of 
efficacy for TCM (P = 0.001), and interpretation of the results with TCM theories (P < 
0.001). As for the previously mentioned items, non-Chinese articles had poorer reporting 
compared with Chinese articles. In contrast, Chinese articles were inferior to non-Chinese 
articles in terms of quality control surveillance of interventions (P = 0.021).
The assessment outcomes of scientific rigor and ethics of placebo-controlled trials 
are presented in Table IV. Emergency plan against aggravated disease conditions was 
neglected in a large proportion of both Chinese and non-Chinese trials. Non-Chinese 
trials tended to have a higher quality compared with Chinese trials in regard to certain 
aspects: informed consent obtained from subjects (P < 0.001); ethics committee 
approval (P < 0.001); and estimation of sample size (P < 0.001). However, compared 
with non-Chinese trials, basic interventions of diseases were adopted more frequently 
in Chinese trials (P = 0.003).
DISCUSSION
Regardless of whether studies were conducted in China, a mean of <51% of the neces-
sary items on the modified CONSORT checklist were reported in the published ar-
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Figure 2.  The mean number of Consolidated Standard of Reporting Trials (CONSORT) 
items reported across all publishing time intervals in randomized placebo-
controlled trials of traditional Chinese medicine compound formulations. *P < 
0.05 versus Chinese trials; †P < 0.05 versus phase 1; ‡P < 0.05 versus phase 1 
and 2.
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ticles. The data of our study are similar to that found by Gagnier et al,14 who assessed 
the reporting quality of RCTs of herbal medicine and found that 45.05% of the 
CONSORT items were reported in these articles. Huwiler-Müntener et al26 also 
reported that 60 randomized placebo-controlled trials published in English-language 
journals from 1985 to 1997 had a mean of 12.5 of the 25 items (50%) on the 1996 
CONSORT checklist. Across all included trials of our study, the information reported 
was inadequate, particularly in Chinese trials. Many trials failed to report the neces-
sary information, especially the method of sequence generation, allocation conceal-
ment, implementation of randomization, evaluation of blinding, flow diagram, esti-
mation of sample size, and clear definition of outcome measures.
Randomization, blinding, and establishment of the control group are 3 principles 
of clinical research design. Patients receiving placebo may seek other treatment, espe-
Table III.  Assessment using some indices reflecting characteristics of traditional 
Chinese medicine (TCM) and other indices that should be reported in placebo-
controlled trials.
Non-Chinese 
 Chinese Trials,* Trials,† 
 No. (%) No. (%) Statistic 
Items (n = 324) (n = 51) Value P
The composition of TCM 
compound formulation 292 (90.12) 49 (96.08) 1.242‡ 0.265
Actions and indications  
of TCM compound formulation 
and modern pharmacologic 
evidence of each active ingredient 150 (46.30) 18 (35.29) 2.157§ 0.142
TCM syndrome type 137 (42.28) 3 (5.88) 24.957§ <0.001
TCM diagnostic criteria for  
each disease 113 (34.88) 1 (1.96) 22.564§ <0.001
Evaluation criteria of TCM for 
therapeutic effects 69 (21.30) 1 (1.96) 10.851§ 0.001
Interpretation of the results  
with TCM theories 208 (64.20) 1 (1.96) 69.181§ <0.001
Quality control surveillance  
of interventions 11 (3.40) 6 (11.76) 5.329‡ 0.021
The manufacturing process of  
placebo and the difference in  
sensory characteristics between  
the study preparation and the  
placebo 203 (62.65) 32 (62.75) 0.000§ 0.990
Number and name of  
trial registration 5 (1.54) 3 (5.88) 2.167‡ 0.141
*Trials conducted in mainland China, Hong Kong, and Taiwan.
†   Trials conducted outside of mainland China (eg, Japan, United States, Australia, Korea, and United 
Kingdom).
‡  Continuity correction χ2 test.
§ Pearson χ2 test.
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cially if there is established effective treatment available, and this may lead to biased 
results. Thus, in placebo-controlled trials, randomization and blinding play more 
important roles in reducing biases.22
RCTs provide the best evidence for efficacy of health care interventions.19 However, 
if the method of sequence generation is used erroneously, biased results are easy to 
generate. The method of random-sequence generation, allocation concealment, and 
implementation of randomization should be adequately described in the reports of 
RCTs. Otherwise, readers cannot identify the authenticity and reliability of random-
ized trials, and the likelihood of bias in group assignment. In our research, 104 (32.10%) 
of the Chinese articles and 20 (39.22%) of the non-Chinese articles described the 
specific method of sequence generation; 23 (7.10%) Chinese and 9 (17.65%) 
non-Chinese articles reported allocation concealment; and 18 (5.56%) Chinese and 
7 (13.73%) non-Chinese articles reported implementation of randomization. As in the 
present study, Linde et al27 also found that most CAM trials, which were collected for 
5 previously published systematic reviews on herbal medicine (Hypericum for depres-
sion, Echinacea for common cold), homeopathy, and acupuncture, did not report the 
generation of random sequence and adequate method of allocation concealment. Of 
the 42 trials on herbal medicine, 13 (31%) and 11 (26%) adequately reported the 
generation of random sequence and method of allocation concealment, respectively.
Blinding is important to reduce the bias of implementation and evaluation. If 
blinding is done, the success of blinding should be evaluated22; if blinding is not 
done, the reasons for not blinding should be reported.28 Blinded groups should be 
Table IV.  Assessment of the scientific rigor and ethics of placebo-controlled trials of 
traditional Chinese medicine compound formulations.
Non-Chinese 
 Chinese Trials,* Trials,† 
 No. (%) No. (%) Statistic 
Items (n = 324) (n = 51) Value P
Trials that may be acceptable 
to use placebo alone in the  
control group 198 (61.11) 39 (76.47) 4.470‡ 0.035
Basic interventions of diseases 147 (45.37) 12 (23.53) 8.607‡ 0.003
Informed consent obtained  
from subjects 107 (33.02) 47 (92.16) 63.662‡ <0.001
Ethics committee approval 34 (10.49) 42 (82.35) 140.807‡ <0.001
Emergency plan against  
aggravated disease conditions 20 (6.17) 5 (9.80) 0.441§ 0.506
Estimation of sample size 18 (5.56) 18 (35.29) 41.543§ <0.001
*Trials conducted in mainland China, Hong Kong, and Taiwan.
†   Trials conducted outside of mainland China (eg, Japan, United States, Australia, Korea, and United 
Kingdom).
‡ Pearson χ2 test.
§  Continuity correction χ2 test.
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described. Authors should avoid using terms such as “single-blind” or “double-blind” 
because such terms are not well understood.29 The results of our study found that 
blinding was used in 205 (63.27%) of the Chinese trials, whereas it was adopted in 
49 (96.08%) of the non-Chinese trials. Only 5 (1.54%) of the Chinese articles and 
4 (7.84%) of the non-Chinese articles reported the success of blinding. Another review 
article also found similar results; 4 (2.1%) of the included 191 randomized placebo-
controlled trials from leading general medicine and psychiatry journals assessed the 
success of blinding.30
Although the necessary information reported was inadequate across all of the in-
cluded trials of our study, the mean number of CONSORT items reported increased 
over time regardless of whether it was a Chinese or non-Chinese trial. Moreover, the 
difference in the mean number of CONSORT items reported between Chinese and 
non-Chinese trials was decreasing. This may be associated with the generalization and 
application of the CONSORT statement worldwide. The findings were similar to that 
of Gagnier et al,14 who also found a significant increase over time in the number of 
the reported items in RCTs of herbal medicines. For each decade of publication, the 
mean number of the reported items across trials of a total of 42 items was as follows: 
1970s (12 of the 42 items); 1980s (15); 1990s (18.5); and 2000s (20).
Patients experiencing the same disease may manifest different TCM syndrome 
types.31 From the view of TCM, diagnosis and treatment of diseases combined with 
syndrome differentiation are vitally important. If syndrome differentiation was ig-
nored in any TCM therapies, the therapeutic effect would be affected. In this study, 
137 (42.28%) of the Chinese articles reported TCM syndrome type, 113 (34.88%) 
reported TCM diagnostic criteria of diseases, and 69 (21.30%) reported evaluation 
indices of efficacy for TCM, whereas in non-Chinese articles, only 3 (5.88%) reported 
TCM syndrome type and 1 (1.96%) reported TCM diagnostic criteria of diseases and 
evaluation indices of efficacy for TCM. Whether the articles were Chinese or non-
Chinese, the reported information regarding the characteristics of TCM was inade-
quate. Many investigators only paid attention to the diagnosis criteria and efficacy 
evaluation indices of Western medicine, but neglected syndrome differentiation and 
evaluation indices of TCM for therapeutic effects. As for the TCM characteristic indi-
ces, the reporting quality of Chinese trials was significantly better than that of non-
Chinese trials, which may be related to the fact that TCM originates in China. It is 
important to conduct TCM research in line with relevant international practice. At 
present, one of the best methods may be to combine the concept of diseases (defined 
by Western medicine) with that of syndrome type (defined by TCM) in the diagnosis 
and treatment of diseases.32
In placebo-controlled trials, placebo should be designed to smell, appear, and taste 
indistinguishably from the trial preparation.23 However, due to the unique sensory 
characteristics of Chinese herbal medicine, it is difficult to make a perfectly matching 
placebo, which makes it easily identifiable. Although capsules may reduce the differ-
ence between the study medication and the placebo, the use of capsules is limited 
because of certain factors, such as change of efficacy and characteristics of drugs.33 As 
shown in the present study, 203 (62.65%) of the Chinese articles described the manu-
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facturing process of placebo and the difference in sensory characteristics between the 
study preparation and the placebo; 165 provided only a brief description. Of the non-
Chinese articles, 32 (62.75%) reported this item; 15 provided only a brief description. 
In a large number of trials, it was difficult to determine whether the herbal medica-
tions could resemble placebo in all aspects.
The placebo satisfied the criteria of application (ie, the scientific rigor of placebo 
application). For the standard of placebo application, the Declaration of Helsinki has 
been amended 6 times, raising various controversies.34 Smoak35 pointed out that, 
generally, subjects in the control group should receive an established effective inter-
vention. For example, regardless of the trial or control group, patients with coronary 
artery disease should receive oral or intravenous nitrates, β-blockers, anticoagulants, 
and/or calcium channel blockers according to the state of illness. Use of placebo may 
be acceptable when there is no established effective intervention; when withholding 
effective intervention would mostly expose subjects to temporary discomfort or delay 
in relief of symptoms; when use of effective intervention would not yield scientifically 
reliable results; and when the use of placebo would not add any serious or irreversible 
harm to the subjects.24 In this study, we found that it was unethical to use placebo 
alone in 38.89% of the Chinese trials and 23.53% of the non-Chinese trials. Addi-
tionally, basic interventions were not administered for the treatment of diseases in 
177 (54.63%) of the Chinese trials and 39 (76.47%) of the non-Chinese trials. The 
lack of basic interventions in some organic diseases that had well established measures 
available, such as coronary heart disease, hypertension, cerebral infarction, asthma, and 
chronic heart failure, might result in serious or irreversible harm. Although results 
can be obtained from these trials, the requirement of placebo application could not be 
satisfied, which were contrary to the scientific rigor of placebo application.
Furthermore, the application of placebo without pharmaceutical intervention in-
volves some ethical issues. All trials must follow the principle of maximum benefit 
with minimum harm. In placebo-controlled trials, the people involved are consenting 
volunteers.36 The contents regarding the ethics of placebo should include receiving 
institutional review board approval and obtaining informed written consent from all 
participating subjects. Additionally, in order to protect the safety and interests of 
subjects, it is essential that an emergency plan be formulated before the test. Through 
this way, effective measures can be taken to minimize harm in case of emergency or 
aggravated disease conditions. The results of our study found that institutional review 
board approval and informed written consent were obtained in 34 (10.49%) and 
107 (33.02%) of the Chinese trials, respectively, while they were obtained in 42 (82.35%) 
and 47 (92.16%) of the non-Chinese trials. The estimation of sample size can also 
reflect the ethics of placebo application because it can avoid subjecting an excess 
number of patients to poor efficacy. In the present study, 18 (5.56%) Chinese and 
18 (35.29%) non-Chinese articles reported the estimation of sample size.
There are 2 noteworthy limitations of the present study. First, only English- or 
Chinese-language articles were included. The influence of language of publication on 
reporting quality is unknown. Therefore, the results of our study are only applicable 
to English- and Chinese-language reports. Second, research of TCM compound for-
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mulations accounted for the majority of the TCM trials in China, while research on 
Chinese herbal monomer or single-herb treatment accounted for the majority of TCM 
trials in non-Chinese countries. This led to a great difference in the number of trials 
between the 2 groups.
CONCLUSIONS
The results indicate that the reporting quality of randomized placebo-controlled trials 
of TCM compound formulation interventions has improved over time, but still re-
mains poor regardless of country of origin (Chinese or non-Chinese trials). Across all 
included trials, particularly Chinese trials, the reporting of the items recommended 
by the CONSORT guidelines was inadequate. The gap in the number of the reported 
CONSORT items between Chinese trials and non-Chinese trials narrowed over time. 
Moreover, a large number of trials of TCM, especially non-Chinese trials, lacked syn-
drome differentiation and the characteristics of TCM. More importantly, in many 
placebo-controlled trials, especially in Chinese patients, the use of placebo was ethi-
cally contradictory and unjustified.
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